Gail Schulze
Director/Board Member presso CERUS CORPORATION
Patrimonio netto: 269 056 $ in data 29/02/2024
Profilo
Gail Gaumer Schulze is on the board of Cerus Corp.
In her past career she occupied the position of Chairman at ZP Opco, Inc., Chief Executive Officer & Director at YM Biosciences USA, Inc., President at YM BioSciences, Inc., President, Chief Executive Officer & Director at Eximias Pharmaceutical Corp., COO & Deputy Chief Executive Officer at Aventis Behring, President-Renal Division Europe at Baxter Healthcare Corp.
and Vice President of Allegiance Healthcare Corp.
Gail Gaumer Schulze received an undergraduate degree from the University of California, Santa Cruz and an MBA from Stanford Graduate School of Business.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
CERUS CORPORATION
0.07% | 07/06/2023 | 123 420 ( 0.07% ) | 269 056 $ | 29/02/2024 |
Posizioni attive di Gail Schulze
Società | Posizione | Inizio |
---|---|---|
CERUS CORPORATION | Director/Board Member | 25/10/2007 |
Precedenti posizioni note di Gail Schulze
Società | Posizione | Fine |
---|---|---|
ZP Opco, Inc.
ZP Opco, Inc. Pharmaceuticals: MajorHealth Technology ZP Opco, Inc. operates as a biopharmaceutical company that develops transdermal delivery technology for therapeutic indications. The company was founded by Peter E. Daddona and Frank D. Stonebanks in 2006 and is headquartered in Fremont, CA. | Chairman | 01/06/2012 |
YM Biosciences USA, Inc.
YM Biosciences USA, Inc. Pharmaceuticals: MajorHealth Technology YM Biosciences USA, Inc. develops and commercializes pharmaceutical products. The company was founded on November 23, 2005 and is headquartered in Wayne, PA. | Chief Executive Officer | 01/03/2007 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | President | 01/03/2007 |
Aventis Behring | Chief Operating Officer | 01/01/2004 |
Allegiance Healthcare Corp.
Allegiance Healthcare Corp. Medical DistributorsDistribution Services Allegiance Healthcare Corp. manufactures and distributes pharmaceutical products. It offers medical, surgical, and laboratory products. The company provides services to hospitals, laboratories, and others in the health care industries. The company was founded in 1999 and is headquartered in Waukegan, IL. | Corporate Officer/Principal | 01/01/1997 |
Formazione di Gail Schulze
University of California, Santa Cruz | Undergraduate Degree |
Stanford Graduate School of Business | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
CERUS CORPORATION | Health Technology |
Aziende private | 7 |
---|---|
Baxter Healthcare Corp.
Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | Health Technology |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Eximias Pharmaceutical Corp.
Eximias Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology Eximias Pharmaceutical Corp. develops pharmaceuticals for treatment of cancer disorders. It offers its services in the mid-Atlantic areas. The company is headquartered in Berwyn, PA. | Health Technology |
ZP Opco, Inc.
ZP Opco, Inc. Pharmaceuticals: MajorHealth Technology ZP Opco, Inc. operates as a biopharmaceutical company that develops transdermal delivery technology for therapeutic indications. The company was founded by Peter E. Daddona and Frank D. Stonebanks in 2006 and is headquartered in Fremont, CA. | Health Technology |
Allegiance Healthcare Corp.
Allegiance Healthcare Corp. Medical DistributorsDistribution Services Allegiance Healthcare Corp. manufactures and distributes pharmaceutical products. It offers medical, surgical, and laboratory products. The company provides services to hospitals, laboratories, and others in the health care industries. The company was founded in 1999 and is headquartered in Waukegan, IL. | Distribution Services |
Aventis Behring | Health Technology |
YM Biosciences USA, Inc.
YM Biosciences USA, Inc. Pharmaceuticals: MajorHealth Technology YM Biosciences USA, Inc. develops and commercializes pharmaceutical products. The company was founded on November 23, 2005 and is headquartered in Wayne, PA. | Health Technology |